A nanodiamond-formulated plant protein induces robust immunity against porcine epidemic diarrhea virus in piglets

✅ 全文

纳米金刚石配制的植物蛋白诱导仔猪对猪流行性腹泻病毒的强效免疫

作者 Thuong Thi Ho; Hoai Thu Tran; Phuong Minh Thi Nguyen; Huyen Thi Bui; Hien Thu Thi Nguyen; Thao Bich Thi Le; Minh Dinh Pham; Wesley Wei-Wen Hsiao; Dai Huu Nguyen; Ha Hoang Chu; Ngoc Bich Pham; Hang Thu Thi Hoang 期刊 Frontiers in Immunology 发表日期 2025 卷/期/页码 Vol. 16 ISSN 1664-3224 DOI 10.3389/fimmu.2025.1674222 类型 原创研究 (Original Research)

📄 英文摘要 English Abstract

EN

Porcine epidemic diarrhea virus (PEDV) continues to be a major infectious threat in swine, especially endangering piglets. The COE and S1D domains have been identified as crucial antigens suitable for designing subunit vaccines. Nanodiamonds (NDs), owing to their biocompatibility, large surface area, and modifiable surfaces, have gained interest as novel carriers to improve recombinant protein vaccines. In this study, we transiently expressed a COE-S1D fusion protein containing the GCN4pII motif (COE-S1D-pII) in Nicotiana benthamiana. The recombinant protein was subsequently mixed with nanodiamonds at various mass ratios to form COE-S1D:ND complexes. SDS-PAGE and Western blot analyses identified the optimal ratio as 1:24 (w/w). Additional size, zeta and morphology characterization of these complexes was carried out. We then assessed the immune response of the COE-S1D:ND complex (1:24, w/w) in pregnant sows and their piglets, comparing it to the response induced by the free COE-S1D-pII protein. After administering a booster dose, the COE-S1D:ND mixture significantly enhanced PEDV-specific IgG and COE-S1D-specific IgA levels, as well as neutralizing antibody titers, as measured by ELISA and virus neutralization assays in their piglets. Overall, the results highlight that ND nanoparticles can strengthen both systemic and mucosal immunity, supporting the potential of using plant-produced COE-S1D-pII protein in combination with nanodiamonds as a next-generation subunit vaccine candidate against PEDV.

📄 中文摘要 Chinese Abstract

中文
猪流行性腹泻病毒(PEDV)仍然是猪群中的主要传染性疾病威胁,尤其危及仔猪。COE和S1D结构域已被鉴定为设计亚单位疫苗的关键抗原。纳米金刚石(NDs)因其良好的生物相容性、大比表面积和可修饰的表面特性,作为新型载体在重组蛋白疫苗领域受到广泛关注。 在前期研究中,源自高致病性越南PEDV G2a毒株的COE蛋白与pII基序融合后,能够在免疫接种的妊娠母猪所产仔猪中诱导针对PEDV G2a毒株的保护性免疫应答。然而,检测到的中和抗体滴度仍不理想,需要进一步提高以增强保护效力并拓宽保护谱,特别是针对越南流行的PEDV G2b优势毒株。扩展的COE-S1D片段——包含COE区域及相邻的S1D中和表位——有望扩大抗原覆盖范围。迄今为止,尚未有研究报道COE-S1D蛋白与pII基序融合后在植物中的瞬时表达,也未见其在动物模型中的免疫原性研究。

📋 英文结构化总结 English Structured Summary

全文整理

EN

Background:

Porcine epidemic diarrhea virus (PEDV) continues to be a major infectious threat in swine, especially endangering piglets. The COE and S1D domains have been identified as crucial antigens suitable for designing subunit vaccines. Nanodiamonds (NDs), owing to their biocompatibility, large surface area, and modifiable surfaces, have gained interest as novel carriers to improve recombinant protein vaccines.

In previous studies, a COE protein derived from a highly virulent Vietnamese PEDV G2a strain, when fused with the pII motif, elicited protective immune responses in piglets born to vaccinated pregnant sows against PEDV G2a strain. Nevertheless, the neutralizing antibody titers detected remained suboptimal and needed improvement for stronger and broader protection, especially against predominant PEDV G2b strains circulating in Vietnam. The extended COE-S1D fragment—including both the COE region and the adjacent S1D neutralizing epitope—offers the potential to expand antigenic coverage. To date, no studies have reported the transient expression of the COE-S1D protein fused with the pII motif in plants, nor its immunogenicity in animal models.

Methods:

In this study, we transiently expressed a COE-S1D fusion protein containing the GCN4pII motif (COE-S1D-pII) in *Nicotiana benthamiana*. The recombinant protein was subsequently mixed with nanodiamonds at various mass ratios to form COE-S1D:ND complexes. SDS-PAGE and Western blot analyses identified the optimal ratio as 1:24 (w/w). Additional size, zeta and morphology characterization of these complexes was carried out.

We then assessed the immune response of the COE-S1D:ND complex (1:24, w/w) in pregnant sows and their piglets, comparing it to the response induced by the free COE-S1D-pII protein. Measurements were performed by ELISA and virus neutralization assays.

Results:

After administering a booster dose, the COE-S1D:ND mixture significantly enhanced PEDV-specific IgG and COE-S1D-specific IgA levels, as well as neutralizing antibody titers, as measured by ELISA and virus neutralization assays in their piglets. The optimal mass ratio for complex formation was determined as 1:24 (w/w) by SDS-PAGE and Western blot.

Data Summary:

The optimal mass ratio of COE-S1D-pII protein to nanodiamonds was found to be 1:24 (w/w). The COE-S1D:ND complex significantly enhanced PEDV-specific IgG, COE-S1D-specific IgA, and neutralizing antibody titers compared to the free COE-S1D-pII protein. No specific numerical values for antibody titers or statistical measures are provided in the extracted text.

Conclusions:

Overall, the results highlight that ND nanoparticles can strengthen both systemic and mucosal immunity, supporting the potential of using plant-produced COE-S1D-pII protein in combination with nanodiamonds as a next-generation subunit vaccine candidate against PEDV.

Practical Significance:

Porcine epidemic diarrhea (PED) remains a significant infectious threat to swine production worldwide, especially in Asia, where repeated outbreaks continue to result in considerable economic losses. Despite ongoing efforts, a vaccine that effectively protects immunologically naïve pigs against PEDV is still lacking. The findings of this study support the potential of the nanodiamond-formulated plant protein as a next-generation subunit vaccine candidate to address this need.

📋 中文结构化总结 Chinese Structured Summary

中文

背景:

猪流行性腹泻病毒(PEDV)仍然是猪群中的主要传染性疾病威胁,尤其危及仔猪。COE和S1D结构域已被鉴定为设计亚单位疫苗的关键抗原。纳米金刚石(NDs)因其良好的生物相容性、大比表面积和可修饰的表面特性,作为新型载体在重组蛋白疫苗领域受到广泛关注。

在前期研究中,源自高致病性越南PEDV G2a毒株的COE蛋白与pII基序融合后,能够在免疫接种的妊娠母猪所产仔猪中诱导针对PEDV G2a毒株的保护性免疫应答。然而,检测到的中和抗体滴度仍不理想,需要进一步提高以增强保护效力并拓宽保护谱,特别是针对越南流行的PEDV G2b优势毒株。扩展的COE-S1D片段——包含COE区域及相邻的S1D中和表位——有望扩大抗原覆盖范围。迄今为止,尚未有研究报道COE-S1D蛋白与pII基序融合后在植物中的瞬时表达,也未见其在动物模型中的免疫原性研究。

方法:

本研究在烟草(*Nicotiana benthamiana*)中瞬时表达了含有GCN4pII基序的COE-S1D融合蛋白(COE-S1D-pII)。随后将重组蛋白与纳米金刚石按不同质量比混合,形成COE-S1D:ND复合物。通过SDS-PAGE和Western blot分析确定了最优比例为1:24(w/w)。进一步对这些复合物进行了粒径、Zeta电位和形态学表征。

随后,我们在妊娠母猪及其仔猪中评估了COE-S1D:ND复合物(1:24,w/w)诱导的免疫应答,并与游离COE-S1D-pII蛋白诱导的应答进行了比较。采用ELISA和病毒中和试验进行测定。

结果:

加强免疫后,COE-S1D:ND混合物显著提高了仔猪体内PEDV特异性IgG和COE-S1D特异性IgA水平以及中和抗体滴度,ELISA和病毒中和试验结果均证实了这一点。通过SDS-PAGE和Western blot确定了复合物形成的最优质量比为1:24(w/w)。

数据摘要:

COE-S1D-pII蛋白与纳米金刚石的最优质量比为1:24(w/w)。与游离COE-S1D-pII蛋白相比,COE-S1D:ND复合物显著提高了PEDV特异性IgG、COE-S1D特异性IgA和中和抗体滴度。提取的文本中未提供抗体滴度或统计学指标的具体数值。

结论:

总体而言,研究结果表明纳米金刚石纳米颗粒能够同时增强全身性和黏膜免疫应答,支持将植物源COE-S1D-pII蛋白与纳米金刚石联合应用作为新一代PEDV亚单位疫苗候选物的潜力。

实践意义:

猪流行性腹泻(PED)仍然是全球养猪业面临的重大传染性疾病威胁,尤其在亚洲地区,反复暴发的疫情持续造成重大经济损失。尽管各方不断努力,目前仍缺乏能有效保护免疫空白猪群免受PEDV感染的疫苗。本研究结果支持纳米金刚石配方的植物源蛋白作为新一代亚单位疫苗候选物的潜力,有望满足这一迫切需求。

📖 英文全文 English Full Text

EN

TYPE Original Research PUBLISHED 19 September 2025 DOI 10.3389/fimmu.2025.1674222 OPEN ACCESS EDITED BY Abel A. Ramos Vega, National Polytechnic Institute (IPN), Mexico REVIEWED BY

Victor H. Leyva-Grado, AuroVaccines, United States Mohammad Sadegh Taghizadeh, Shiraz University, Iran *CORRESPONDENCE

Ngoc Bich Pham pbngoc@ib.ac.vn Hang Thu Thi Hoang hanghtt@ib.ac.vn RECEIVED 27 July 2025 ACCEPTED 02 September 2025 PUBLISHED 19 September 2025 CITATION

Ho TT, Tran HT, Nguyen PMT, Bui HT, Nguyen HTT, Le TBT, Pham MD, Hsiao WW-W, Nguyen DH, Chu HH, Pham NB and Hoang HTT (2025) A nanodiamond-formulated plant protein induces robust immunity against porcine epidemic diarrhea virus in piglets. Front. Immunol. 16:1674222. doi: 10.3389/fimmu.2025.1674222 COPYRIGHT

© 2025 Ho, Tran, Nguyen, Bui, Nguyen, Le, Pham, Hsiao, Nguyen, Chu, Pham and Hoang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A nanodiamond-formulated plant protein induces robust immunity against porcine epidemic diarrhea virus in piglets Thuong Thi Ho 1, Hoai Thu Tran 1, Phuong Minh Thi Nguyen 1, Huyen Thi Bui 1, Hien Thu Thi Nguyen 1, Thao Bich Thi Le 1, Minh Dinh Pham 1, Wesley Wei-Wen Hsiao 2, Dai Huu Nguyen 3, Ha Hoang Chu 1,4, Ngoc Bich Pham 1,4* and Hang Thu Thi Hoang 1,4* 1 Institute of Biology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam, 2 Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan, 3 CNC Veterinary Medicine Trading and Production Joint Stock Company,, Ha Noi, Vietnam, 4 Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam

Porcine epidemic diarrhea virus (PEDV) continues to be a major infectious threat in swine, especially endangering piglets. The COE and S1D domains have been identified as crucial antigens suitable for designing subunit vaccines. Nanodiamonds (NDs), owing to their biocompatibility, large surface area, and modifiable surfaces, have gained interest as novel carriers to improve recombinant protein vaccines. In this study, we transiently expressed a COES1D fusion protein containing the GCN4pII motif (COE-S1D-pII) in Nicotiana benthamiana. The recombinant protein was subsequently mixed with nanodiamonds at various mass ratios to form COE-S1D:ND complexes. SDSPAGE and Western blot analyses identified the optimal ratio as 1:24 (w/w). Additional size, zeta and morphology characterization of these complexes was carried out. We then assessed the immune response of the COE-S1D:ND complex (1:24, w/w) in pregnant sows and their piglets, comparing it to the response induced by the free COE-S1D-pII protein. After administering a booster dose, the COE-S1D:ND mixture significantly enhanced PEDV-specific IgG and COE-S1D-specific IgA levels, as well as neutralizing antibody titers, as measured by ELISA and virus neutralization assays in their piglets. Overall, the results highlight that ND nanoparticles can strengthen both systemic and mucosal immunity, supporting the potential of using plant-produced COE-S1D-pII protein in combination with nanodiamonds as a next-generation subunit vaccine candidate against PEDV.

nanodiamond, COE-S1D-pII protein, PEDV, immune response, vaccine, piglets Frontiers in Immunology 01 frontiersin.org Ho et al. 10.3389/fimmu.2025.1674222

against PEDV infection, the levels of neutralizing antibodies in the serum have been associated with enhanced resistance to PEDV (21). This highlights the importance of investigating alternative antigens or antigen combinations that can trigger stronger neutralizing responses to achieve broader protection. In this regard, the extended COE-S1D fragment—which includes both the COE region and the adjacent S1D neutralizing epitope—offers the potential to expand antigenic coverage. To date, no studies have reported the transient expression of the COE-S1D protein (amino acids 499–789) fused with the pII motif in plants, nor its immunogenicity in animal models. To further improve the immunogenicity of these plant-produced COE-S1D-pII proteins, we investigated the potential of incorporating nanodiamonds (ND) as novel nanoparticle-based adjuvants and delivery vehicles. In designing modern protein subunit vaccines that direct immune responses toward defined epitopes, nanoparticles have proven invaluable. Their widespread application as antigen and drug carriers, or as adjuvants, stems from their ability to reduce side effects, increase formulation stability, and vigorously promote humoral immune responses (22, 23). NDs combine several appealing features, such as excellent biocompatibility, easily modifiable surface chemistry, a high capacity to carry antigens, and lower toxicity compared to other carbon nanomaterials (24– 27). In addition, incorporating nanoparticles as vaccine adjuvants has been shown to enhance immune responses (28, 29). In this study, we produced COE-S1D protein in N. benthammiana via transient expression. We aimed to explore whether incorporating NDs could enhance the immunogenicity of plant-produced COE-S1D-pII proteins against PEDV. We assessed immune responses in pregnant sows and their piglets to better represent the target host context. By comparing the immune responses elicited by the COE-S1D-pII: ND formulation (abbreviated as COE-S1D:ND) with those induced by the free plant-based COE-S1D-pII proteins, we aimed to determine the adjuvant potential of nanodiamonds. Overall, our results show that the COE-S1D:ND complex elicits markedly stronger immune responses against a highly virulent PEDV G2b strain than the free COE-S1D protein. This underscores the promise of using nanodiamonds as nanoparticle-based adjuvants in the development of subunit vaccines for PEDV.

Introduction Porcine epidemic diarrhea virus (PEDV) is an RNA virus, which is classified within the genus Alphacoronavirus of the Coronaviridae family (1). PEDV is a primary viral agent responsible for inducing severe watery diarrhea in pigs (2). Although PEDV is capable of infecting pigs at any age, it is particularly devastating in suckling piglets, where it can cause acute enteric disease with mortality rates as high as 80–100% (3). Porcine epidemic diarrhea (PED) thus remains a significant infectious threat to swine production worldwide, especially in Asia, where repeated outbreaks continue to result in considerable economic losses (4, 5). The classical genogroup (G1) PEDV strains are generally associated with mild or low-pathogenic infections, whereas the more virulent genogroup 2 (G2) strains—including subgroups G2a and G2b—have been linked to outbreaks causing mortality rates approaching 100% in suckling piglets (6). In Vietnam, large-scale PEDV outbreaks have largely been driven by G2 strains (7). Despite ongoing efforts, a vaccine that effectively protects immunologically naïve pigs against PEDV is still lacking, underscoring the continued challenge of managing PED outbreaks (8). Among the four structural proteins of PEDV, the Spike (S) protein is crucial for facilitating the virus’s entry into host cells and serves as the principal immunogen, inducing neutralizing antibody responses (9). Owing to these critical functions, the S protein is considered the primary target for subunit vaccine design. Structurally, it comprises two distinct domains: the S1 domain (amino acids 1–789) and the S2 domain (amino acids 790–1383) (10). Within the S1 domain, two major neutralizing epitopes have been identified: the COE epitope (amino acids 499–638) and a recently characterized region, S1D (amino acids 636–789). These epitopes have been shown to stimulate strong neutralizing antibody responses against PEDV, making them attractive candidates for the development of next-generation subunit vaccines (11, 12). To date, the COE and S1D proteins of PEDV have been successfully expressed as fusion proteins with various motifs in multiple heterologous systems, including Escherichia coli (13), yeast (14), mammalian cells (15), and plants (16). Among these platforms, plant-based expression systems—particularly transient expression via agroinfiltration—have emerged as promising strategies owing to their rapid production, scalability, and costeffectiveness (17, 18). In our previous studies, COE protein variants were transiently expressed in N. benthamiana as fusion constructs with the GCN4pII motif (pII), and their immunogenic potential was demonstrated in animal models (19, 20). Notably, the COE protein derived from a highly virulent Vietnamese PEDV G2a strain, when fused with the pII motif (designated COE/G2a-pII), elicited protective immune responses in piglets born to vaccinated pregnant sows against PEDV G2a strain (20). Nevertheless, the neutralizing antibody titers detected in these piglets remain suboptimal and need to be improved to ensure stronger and broader protection, especially against the predominant PEDV G2b strains circulating in Vietnam. Although antibodies produced in sera alone are not enough for complete protection

Method Production and characterization of plantbased COE-S1D-pII protein of PEDV The coding sequence corresponding to amino acids 499–789 of the S protein of PEDV strain NAVET/PEDV/PS6/2010 (genotype G2a) was selected to generate the COE-S1D construct. The nucleotide sequence was codon-optimized for efficient expression in N. benthamiana. The optimized fragment was fused in-frame to a series of functional elements, including: (i) an N-terminal 6×His tag to enable affinity purification and detection; (ii) the GCN4pII motif to facilitate trimerization, and (iii) the KDEL signal for protein

accumulation in the endoplasmic reticulum. This synthetic expression cassette was driven by the Cauliflower mosaic virus (CaMV) 35S promoter and inserted into the pRTRA vector backbone. The assembled cassette was subsequently subcloned into the binary vector pCB301 for Agrobacterium tumefaciens– mediated transient expression in N. benthamiana via vacuum infiltration, following the procedure described previously (19). At five days post-agroinfiltration, the infiltrated N. benthamiana leaf tissues were harvested and immediately frozen at –80 °C for downstream processing. Expression of the COE-S1DpII protein in N. benthamiana leaves was detected and semiquantified by SDS-PAGE and Western blot. Blots were probed with either a monoclonal anti-His tag antibody or porcine sera from pigs immunized with the commercial PEDV AJ1102 strain vaccine (Corning, Wuhan Keqian Biology) as primary antibodies, followed by goat anti-mouse IgG-HRP (Invitrogen) or goat anti-porcine IgG (H+L)-HRP (SouthernBiotech) as secondary antibodies. Signals were visualized and quantified by comparing band intensities against a standard curve generated from H5N1-specific ScFv protein (30), using ImageQuant TL 8.0 software (Cytiva) and an Amersham™ Imager 680. Recombinant COE-S1D-pII protein was extracted and purified from the plant biomass by immobilized metal affinity chromatography (IMAC) and size exclusion chromatography (SEC), as previously described (20). The purified protein fraction was formulated in 50% (v/v) glycerol diluted in 1× PBS (pH 7.4) and kept at –20 °C to maintain structural stability and antigenicity. In addition, the multimeric state of the purified COE-S1D-pII protein was evaluated by chemical cross-linking using BS3 (Bis [sulfosuccinimidyl] suberate) (31). Briefly, one μg of COE-S1DpII protein was reacted with 5 mM BS3 for 30 min at room temperature, then quenched by adding Tris-HCl buffer (pH 8.0) to 50 mM. The products were separated by 4–10% SDS-PAGE under reducing conditions and detected by Western blot using an anti-his tag antibody. The tertiary structure of the COE-S1D protein was modeled using SWISS-MODEL (32), based on a template selected by sequence similarity. Model quality was evaluated by the GMQE and QMEAN scores provided by the server.

Preparation and characterization of COES1D:ND complexes To generate a uniform ND suspension, surface-oxidized nanodiamonds (NDs) were ultrasonically dispersed in deionized water at a concentration of 10 mg/mL. The COE-S1D-pII protein was then added to the ND suspension at mass ratios of 1:6, 1:12, 1:24, 1:36, and 1:48 in phosphate-buffered saline (1× PBS, pH 7.4). To enhance protein adsorption onto the ND surface, the mixtures were gently sonicated on ice for 5 minutes. Following incubation, samples were spun at 13,000 rpm for 15 minutes. The pellets were gently rinsed twice with deionized water to remove unbound proteins and subsequently resuspended in PBS for further analysis. Protein binding efficiency was determined using the Bradford assay, and complex stability was assessed over a period of one week by monitoring particle size and retained protein content. The complexes were characterized by SDS-PAGE and Western blot analysis, following the protocol described previously (33). Samples were combined with 4× SDS-PAGE loading buffer and denatured by heating at 95 °C for 20 minutes. After electrophoresis on a 12% SDS-PAGE gel, proteins were transferred to PVDF membranes at 35 V overnight. Membranes were kept in 5% milk in PBS (pH 7.4) for two hours, incubated with anti−6×His tag antibody (Invitrogen) for two hours, then with goat anti−mouse IgG−HRP (Invitrogen) for one hour. Bands were visualized using DAB (Sigma) in 0.05 M Tris−HCl (pH 7.2). Signal detection and quantification were performed with Amersham™ Imager 680, ImageQuant TL 8.0 (Cytiva), and ImageJ. The COE-S1D:ND complexes were characterized for particle size distribution, polydispersity index (PDI), and zeta potential following the protocol described previously (33). A final concentration of each sample of 50 mg/mL was obtained by diluting in deionized water and measured in triplicate at 37 °C. Hydrodynamic diameter measurements were evaluated using a Zetasizer Nano ZS (Malvern Panalytical), and zeta potential was determined with a Horiba SZ-100 analyzer. Morphological characterization by Transmission Electron Microscopy (TEM) was performed using a JEOL 1400 Flash microscope operating at 120 kV to verify the structural integrity.

Preparation of surface-oxidized NDs Pig immunization To introduce oxygen-containing functional groups, commercial diamond powder (Diamond Innovations, USA) was oxidized by treating it with a 3:1 (v/v) mixture of concentrated sulfuric and nitric acids (H2SO4:HNO3). The oxidation reaction was performed using a Model Discover microwave system (CEM) at approximately 100 °C and 100 W for 3 hours, following the procedure reported (28). After the reaction, residual acids were carefully diluted before collecting the nanodiamonds. All procedures were conducted in a chemical fume hood to minimize exposure to nitrogen dioxide (NO2). Residual acids were carefully diluted before collecting the NDs.

The animal experiments were approved by the Ethics Committee of the Institute of Biology, Vietnam Academy of Science and Technology (VAST), Hanoi. All procedures conformed to the principles of the “3Rs” and complied with Directive 86/609/EEC of the European Communities Council on the protection and use of laboratory animals. Pigs were housed and closely monitored by veterinarians to minimize stress, pain, and discomfort during the experiments. Two weeks prior to immunization, blood samples were collected from pregnant sows for testing of PEDV-IgG, IgA-specific antibodies, and neutralizing

preparation of serial dilutions. Each dilution was combined with 10² TCID50/0.1 mL of a highly virulent Vietnamese G2b strain of PEDV and incubated at 37 °C for an hour to allow antibody–virus interaction. The mixtures were then added to confluent Vero cell monolayers and left for another hour at 37 °C before being gently washed with PBS to remove unbound virus. After incubation, the cell cultures received fresh a-MEM medium containing trypsin and were kept at 37 °C in a CO2 incubator for a period of six days. The neutralizing antibody titer was assessed as the greatest dilution of serum that completely blocked cytopathic effects from appearing in the cell monolayer.

antibodies against PEDV. Six pregnant sows lacking PEDV-IgG, IgA antibodies, and neutralizing antibodies were enrolled. Purified COE-S1D-pII protein (150 μg/dose), the COE-S1D:ND mixture (containing 150 μg COE-S1D protein and 3.6 mg ND per dose), or PBS mixed with ND (3.6 mg/dose) were emulsified with Emulsigen®-D adjuvant (MVP) at an 8:2 ratio. At approximately 80 days of gestation, sows were intramuscularly immunized in the neck on days 0 and 14. Blood samples from sows were obtained at day 0 and day 35 after immunization, while milk samples were obtained on day 35 post-immunization. Piglets (n = 5) born to the immunized sows or the PBS: ND control sow were allowed to suckle and were kept with their dams. Blood samples from all piglets were obtained at 5 days of age for further analysis. All sera and milk were kept at −20 °C until measurement of PEDV-specific IgG and IgA antibody responses by ELISA and determination of PEDVneutralizing antibody titers.

Statistical analysis Data analysis was performed using the Mann–Whitney test in GraphPad Prism version 8.0. Results are reported as mean values with their corresponding standard deviations (SD). Statistical significance between groups was accepted at p-values below 0.05. Significance levels are indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001.

Evaluation of PEDV-specific IgG antibodies by ELISAs Serum samples from sows and piglet sera were tested for PEDVspecific IgG using a commercial ELISA kit (INgezim PEDV 11.PED.K.1/5, Eurofins INGENASA). Piglet sera were diluted 1:100 prior to testing. The S/P (sample-to-positive) ratio was calculated as follows: (sample OD − negative control OD)/ (positive control OD − negative control OD). Samples were considered positive for PEDV-specific IgG if the S/P value exceeded 0.35.

Results Production and characterization of plantbased COE-S1D-pII protein of PEDV To achieve the expression of the COE-S1D-pII protein in N. benthamiana, a plant-based expression vector harboring the target gene was constructed (Figure 1A). This recombinant vector was subsequently introduced into A. tumefaciens through transformation, enabling the delivery of the expression cassette into the plant system. The accumulation of the COE-S1D-pII protein in N. benthamiana tobacco leaves was detected via Western blot analysis using an anti-His antibody. SDS-PAGE and Western blot results confirmed the successful expression of the COE-S1D-pII antigen in tobacco leaves, as evidenced by a band on the membrane with an apparent molecular weight greater than 55 kDa. The theoretical molecular weight of the recombinant monomeric COE-S1D-pII antigen is calculated to be 38.2 kDa. However, the experimentally observed molecular weight of the monomeric COE-S1D antigen was found to be greater than 55 kDa. The difference between the theoretical and observed molecular weights of the COE-S1D-pII antigen may be attributed to glycosylation modifications, which can affect antigen migration and separation during SDS-PAGE. In silico analysis using NetNGlyc 1.0 identified six predicted N-linked glycosylation sites in the COE-S1D region. Such N-glycans are expected to increase the apparent molecular weight and retard electrophoretic migration during SDS-PAGE. This interpretation is consistent with published data showing that the PEDV spike is N-glycosylated (33–35). Importantly, biochemically that PNGase F (but not Oglycosidase) increased the electrophoretic mobility of recombinant PEDV S1, confirming predominant N-linked glycans and their

Evaluation of COE-S1D-specific IgA antibodies by ELISAs Levels of COE-specific IgA in sow milk and piglet sera were measured using an indirect ELISA following the previous protocol described (30), with slight adjustments. In brief, SEC-purified COES1D protein (100 ng per well, at 1 ng/μL) was used to coat 96-well plates overnight at 4 °C in PBS (pH 7.4). Plates were then incubated in 5% skim milk solution in PBS. To detect IgA, milk and serum samples were applied at serial dilutions ranging from 1:10 to 1:640. The plates were then incubated at room temperature for two hours, washed three times with PBS containing 0.05% Tween 20, and subsequently treated with HRP-conjugated goat anti-mouse IgA (SouthernBiotech) diluted 1:5000 in blocking buffer. After 15 min incubation with TMB substrate, the reaction was stopped by adding 1 M H2SO4. Absorbance was measured at 450 nm.

Virus-neutralizing antibody assay To evaluate neutralizing antibodies in pig sera, a virus neutralization assay was performed based on the method described in (33), with some modifications. The serum samples were heat-inactivated at 56 °C for 30 minutes, followed by

Frontiers in Immunology 04 frontiersin.org Ho et al. 10.3389/fimmu.2025.1674222 FIGURE 1

Construction of the expression vector and transient expression of COE-S1D-pII protein in N. benthamiana. (A) The plant expression cassette carries a DNA sequence that encodes COE-S1D fused with the pII motif. The components of the cassette include: the Cauliflower mosaic virus (CaMV) 35 S promoter (CaMV35S-P), LeB4 signal peptide (SP); 6x His tag (6xHis); the GCN4pII motif (pII); c-myc tag (c-myc); endoplasmic reticulum retention signal (KDEL), the CaMV 35 S terminator (CaMV35S-T) (B). The COE-S1D-pII protein, expressed in N. benthamiana leaves, is detected through Western blotting. WT: Wild type N. benthamiana. This detection employs anti-His monoclonal antibody and HRP-conjugated goat anti-mouse IgG antibody. H5N1-specific ScFv antibodies were utilized to establish a standard curve. The accumulation of COE-S1D protein in leaves was then calculated using ImageQuant TL (Cytiva) after capture by the Amersham™ Imager 680 (Cytiva) (C). The COE-S1D protein is also detected in N. benthamiana leaves using anti-PEDV polyclonal antibodies and HRP-conjugated anti-pig IgG as primary and secondary antibodies, respectively.

effect on apparent molecular mass (36). Together, these findings, plus our prediction of six N-glycosylation sites in COE-S1D-pII, might provide a mechanistic explanation for the discrepancy between theoretical and observed molecular weights. The COES1D-pII antigen was not detected in the leaf extracts of nontransgenic N. benthamiana plants. The accumulation level of the recombinant COE-S1D antigen in N. benthamiana leaves was semiquantitatively analyzed using Western blot. The concentration and signal intensity of specific ScFv H5 bands (27) were used to construct a standard curve with ImageQuant TL software (Cytiva) after image acquisition with an Amersham™ Imager 680 (Cytiva). The semi-quantitative analysis revealed that the COE-S1D protein accumulated in tobacco leaves at approximately 115 mg/kg of fresh leaves, accounting for 1.95% of the total soluble protein (Figure 1B). This accumulation level is comparable to that of the COE protein (20). Furthermore, the expression of the recombinant COE-S1D-pII protein in N. benthamiana leaves was also detected using pig sera immunized with the Corning (Wuhan Keqian Biology) vaccine containing the PEDV AJ1102 strain (Figure 1C). The Western blot results in Figure 1C showed a band on the membrane with a molecular weight consistent with the theoretical calculation, approximately 55 kDa. This finding suggests that the COE-S1DpII protein produced in N. benthamiana leaves retains antigenic properties similar to those of the natural PEDV antigen.

Purification and characterization of the oligomeric state of the COE-S1D-pII protein COE-S1D-pII protein was firstly purified by IMAC. The presence of the COE-S1D-pII protein in fractions after IMAC purification was analyzed using SDS-PAGE, followed by Coomassie Blue staining and further confirmation through Western blot analysis (Figures 2A, B). The results indicated that the COE-S1D-pII protein was absent in the flow-through (FT) and wash (W) fractions. The purified COE-S1D-pII antigen was predominantly detected in the elution (E) fraction. The IMAC-purified COE-S1D-pII protein was subjected to SEC and cross-linking analysis to assess its oligomeric characteristics. The oligomeric state of the COE-S1D protein was assessed using BS3 cross-linking. SDS-PAGE analysis combined with Coomassie Blue staining and Western blotting showed a band larger than 250 kDa when BS3 was present (Figure 2C). Along with the results from SEC analysis, this suggests that the COE-S1D protein predominantly forms oligomers under natural conditions. In addition, the SEC purification results, along with Western blot analysis indicated that the COE-S1D-pII protein was detected in fractions 16–24, corresponding to a molecular weight range of approximately 440–669 kDa (Figures 2D, E). The tertiary structure of the COE-S1D-pII protein was constructed using SWISS- 05

Purification and characterization of the multimeric state of the COE-S1D-pII protein. (A, B) Purification of COE-S1D-pII protein by IMAC. Raw extract (RE), flow-through (FT), Wash (W), and elute (E) were separated on SDS-PAGE, then stained in Coomassie staining solution, and washed in destaining solution (A). Raw extract (RE), flow-through (FT), wash (W), and elute (E) were separated on SDS-PAGE, then blotted and detected using a monoclonal anti-c-myc antibody (C) The oligomeric states of COE-S1D were investigated by performing cross-linking reactions. COE-S1D-pII protein was mixed with (+) or without (-) BS3 cross-linkers for 0 mM and 5 mM concentrations, respectively. The mixture was visualized via SDSPAGE and immunoblotting with an anti-His antibody. (D) Size exclusion chromatography (SEC) profiling of COE-S1D-pII protein. A standard kit for molecular weight estimation (75–2000 kDa, GE) was used. (E) COE-S1D-pII Protein in SEC fractions was identified through Western blot analysis. (F) The tertiary structure of the COE-S1D-pII protein was predicted using the SWISS-MODEL homology modeling server. Red regions are strongly hydrophobic, blue regions are strongly hydrophilic, and purple regions are intermediate, containing mixed or moderately hydrophobic residues.

blot analyses were performed (Figures 3A, B). Results from the Bradford assay and Western blot confirmed successful adsorption of COE protein onto the ND. Analysis using ImageJ software revealed that mixing COE-S1D-pII protein with ND at mass ratios of 1:6, 1:12, and 1:24 (w/w) resulted in an increase in protein adsorption efficiency from 39% to 57% and then to 85.3%, respectively. However, further increasing the amount of ND to ratios of 1:36 and 1:48 (w/w) did not significantly improve adsorption levels. Consequently, the 1:24 (w/w) ratio was selected for subsequent experiments. The hydrodynamic diameter of the ND displayed a mean hydrodynamic diameter of 200.2 nm, while the COE-S1D:ND complexes measured slightly larger at 433.6 nm (Figures 3C, D). After coating ND particles with COE-S1D-pII protein (pI 5.6, negatively charged at pH 7.4), the zeta potential of complexes increased from –77.5 mV to –48.2 mV (Table 1). This shift might indicate adsorption of positively charged residues (e.g., Lys and Arg) onto the ND surface, partially neutralizing its surface charge, while the complex remained negatively charged overall due to the net negative charge of the protein. Alterations in both particle size

MODEL, based on the cryo-electron microscopy (cryo-EM) structure of the PEDV S glycoprotein (PDB ID: 6VV5.1.A) as a template (Figure 2F). This template shares a sequence identity of 95.65% with the COE-S1D protein, supporting the accuracy of the model. The predicted model yielded a GMQE score of 0.75 and a QMEANDisCo Global score of 0.80 ± 0.05, indicating overall sound quality and reliability of the structure for downstream analyses. The resulting model predicted that the COE-S1D-pII protein forms a homo-trimer, consistent with the trimeric organization of the native PEDV spike glycoprotein.

Characterization of the COE-S1:ND complexes The COE-S1:ND complexes were prepared by sonicating physical mixtures of COE-S1D-pII protein and ND particles at varying mass ratios (1:6, 1:12, 1:24, 1:36, and 1:48). To identify the ratio that provided the highest binding efficiency of COE-S1D-pII protein to the ND surface, Bradford assay, SDS-PAGE, and Western

Frontiers in Immunology 06 frontiersin.org Ho et al. 10.3389/fimmu.2025.1674222 FIGURE 3

Optimization and characterization of the COE−S1D:ND complexes. (A) COE-S1D protein (500 ng/µL) was mixed with ND at different mass ratios (1:6–1:48, w/w) in 1X PBS (pH 7.4) and sonicated for 5 min at 4°C. After centrifugation, particles were washed twice with deionized water and resuspended in 1X PBS (pH 7.4). Free and complexed COE-S1D:ND were analyzed by 12% SDS−PAGE, transferred to membranes, and detected using anti−His tag antibody and HRP−conjugated secondary antibody; (B) The percentage of COE-S1D-pII protein bound to ND at different mixing ratios was quantified using ImageJ software based on Western blot images. Hydrodynamic size distribution profiles of ND nanoparticles (C), and the COE: S1D:ND complexes (1:24, w/w) (D) dispersed in water. (E) TEM images of the COE-S1D:ND complexes (1:24, w/w) at a magnification of 50 nm.

occurring during complex formation. Furthermore, TEM observations imply that single COE-S1D protein molecules may bridge two distinct nanoparticles, leading to the clustered appearance observed in the micrographs. Collectively, these results demonstrate that the COE-S1D-pII protein was effectively attached to the ND surfaces, resulting in the formation of COES1D:ND complexes as intended.

TABLE 1 Physicochemical characteristics of ND and COE-S1:ND complexes. Structure Zeta potential (mV) Hydrodynamic size (nm) PDI ND -77.5 200.2 0.127 COE-S1D:ND -48.2 433.6 0.25

and zeta potential were observed the COE-S1D:ND complexes suggests that the adsorption of COE-S1D-pII protein onto the surface of ND. Additionally, the COE-S1D:ND complexes showed a higher polydispersity index (PDI = 0.251) compared to the ND alone (PDI = 0.127), indicating a wider variation in particle sizes after complex formation (Table 1). These observations suggest partial aggregation and/or heterogeneous adsorption of protein molecules on the ND surface. Nevertheless, the final PDI remained below 0.3, indicating that the COE-S1D:ND complexes maintained an acceptable level of colloidal stability for vaccine applications. The morphology and structural features of COE-S1D:ND complexes were assessed by TEM (Figure 3E). TEM images revealed that COE-S1D:ND had irregular morphologies. The observed heterogeneity in particle size and shape may stem from differences in protein adsorption levels or partial aggregation

The COE-S1:ND mixture induced stronger humoral and mucosal responses against PEDV than the free COE-S1D-pII protein in pregnant sows The immunogenicity of the COE-S1D-pII protein and the mixture of COE-S1D protein and ND (1:24, w/w) were assessed in pregnant sows according to the immunization protocol shown in Figure 4A. On day 35 post-immunization (pi), PEDV-specific IgG antibodies were detected in the serum of the sow immunized with COE-S1D-pII, with an S/P mean ratio of 1.03 (Figure 4B). Meanwhile, the sow vaccinated with COE-S1D:ND showed a higher PEDV-specific IgG response, with a mean S/P ratio of 2.04. However, the difference in PEDV-specific IgG antibodies between the two groups was not statistically significant (p = 0.293

Humoral and mucosal immune responses in pregnant sows vaccinated with COE-S1D-pII protein or COE-S1D:ND complexes or PBS:ND. (A) Diagram illustrating the immunization schedule for pregnant sows (approximately day 80 of gestation, n=2 per group) and their piglets (n=5 per group). Black arrows indicate vaccination time points, while red arrows show blood sampling times. (B) PEDV-specific IgG concentrations in sera from sows immunized with COE-S1D-pII, COE-S1D:ND complexes, or PBS: ND controls were evaluated using a commercial ELISA kit. Samples with S/P ratios above 0.35 were considered positive for PEDV-specific IgG. (C) COE-specific IgA antibody levels in sow milk were determined by ELISA, using SEC-purified COE-S1D-pII protein as the capture antigen. (D) Neutralizing antibody titers in sow sera were evaluated using a virusneutralization assay with the highly virulent PEDV G2b strain (100 TCID50/0.1 mL). VN titers ≥ 8 were considered indicative of PEDV-neutralizing antibodies. Data are shown as mean ± standard deviation (SD). Statistical significance was defined as p < 0.05. Levels of statistical significance are indicated as follows: *p < 0.05; **p < 0.01; **** p < 0.0001. ns, not significant.

Overall, these findings indicate that vaccination with COE-S1D: ND induced more robust humoral and muscosal immune responses in pregnant sows compared to immunization with COE-S1D-pII protein alone. In particular, a statistically significant increase in IgA levels was observed in the COE-S1D:ND group. Although IgG and neutralizing antibody titers tended to be higher in the COE-S1D: ND group, the differences were not statistically significant.

> 0.05). In contrast, no PEDV-specific IgG antibodies were detected in the serum of the control sow that received PBS: ND. Similarly, on day 35 , pi, COE-S1D-specific IgA antibodies were detected in the milk of the sows vaccinated with COE-S1D-pII, with a mean endpoint IgA titer of 60 (Figure 4C). In comparison, the sows immunized with COE-S1D:ND exhibited a 2-fold higher IgA response, reaching a mean endpoint IgA titer of 126. This difference in COE-S1D-specific IgA antibodies between the two groups was statistically significant (p = 0.0014 < 0.01). In contrast, no COES1D-specific IgA antibodies were detected in the serum of the PBS: ND control sows. Neutralizing antibody titers against a highly virulent PEDV G2b strain were measured using a virus neutralization assay. On day 35 post-immunization (pi), the sows immunized with COE-S1D-pII developed a virus-neutralizing mean titer of 20 (Figure 4D), whereas the sows vaccinated with COE-S1D:ND showed a slightly higher VN mean titer of 24. However, the difference in neutralizing antibody titers between the two groups was not statistically significant (p = 0.8108 > 0.05). In contrast, no neutralizing antibodies against PEDV were detected in the serum of the PBS: ND control sows.

COE-S1D:ND complex outperforms COES1D protein in inducing humoral and mucosal immunity in piglets As antibodies present in colostrum and milk from vaccinated sows can be transferred to piglets through suckling, passive immunity in the offspring was evaluated using ELISA and virusneutralization assays. PEDV-specific IgG antibodies were detected in the sera of 5-day-old piglets born to the sows immunized with COE-S1D-pII. PEDV-specific IgG antibodies were detected in the serum of piglets born to the sows immunized with COE-S1D-pII, with an S/P mean ratio of 1.41. Meanwhile, the piglets born to the

sows vaccinated with COE-S1D:ND showed a higher PEDVspecific IgG response, reaching an S/P mean ratio of 2.39. The difference in PEDV-specific IgG antibodies between the two groups was statistically significant (p = 0.0218 < 0.05). In contrast, no PEDV-specific IgG antibodies were detected in the serum of the control piglets born to the sows that received PBS: ND (Figure 5A). Similarly, COE-S1D-specific IgA antibodies were present at high levels in the sera of these 5-day-old piglets born to the sows vaccinated with COE-S1D-pII, with a mean endpoint IgA titer of 120. In comparison, the sows immunized with COE-S1D:ND exhibited a 2.3-fold higher IgA response, reaching a mean endpoint IgA titer of 272. The difference in COE-S1D-specific IgA antibodies between the two groups was statistically significant (p = 0.0006 < 0.001). In contrast, no COE-S1D-specific IgA antibodies were detected in the serum of the PBS: ND control piglet (Figure 5B). Virus-neutralizing antibodies against a highly virulent PEDV G2b strain were also identified in sera of these 5-day-old piglets. The piglets born to the sows immunized with COE-S1D-pII had a virus-neutralizing titer of 30.8, whereas the piglets born to the sows vaccinated with COE-S1D:ND showed a 1.6-fold higher VN mean

titer of 49.6. The difference in virus-neutralizing antibodies between the two groups was statistically significant (p = 0.0431 < 0.05). In contrast, no neutralizing antibodies against PEDV were detected in the serum of the PBS: ND control piglets (Figure 5C). Taken together, these results demonstrate successful passive transfer of PEDV-specific IgG, COE-specific IgA, and neutralizing antibodies from the immunized pregnant sows to their piglets via colostrum and milk. Furthermore, piglets born to sows immunized with the COE-S1D:ND complex consistently exhibited stronger antibody responses compared with piglets from sows immunized with COE-S1D-pII protein.

Discussion NDs belong to a class of carbon-based nanomaterials characterized by a sp³ crystalline lattice, the same structure that imparts natural diamonds with remarkable hardness and insulating properties. In addition to their physical characteristics, nanodiamonds (NDs) are highly regarded in biomedical research for their excellent biocompatibility, stability in vivo, and flexible

FIGURE 5

Evaluation of maternally derived antibodies in piglets born to immunized sows at day 5 postpartum. Data are expressed as mean ± standard deviation (SD). A statistically significant difference is defined as one where p < 0.05. (A) Levels of PEDV-specific IgG in sera of piglets born to sows (n=5 per group) immunized with COE-S1D-pII or COE-S1D:ND or PBS, quantified using a commercial ELISA kit. Samples with S/P ratios greater than 0.35 were classified as positive for PEDV-specific IgG. (B) COE-S1D-specific IgA concentrations in piglet sera (n = 5 per group) were determined by ELISA, using SEC-purified COE-S1D-pII protein as the coating antigen. (C) Virus-neutralizing antibody titers in piglet sera were measured via a virus neutralization assay against the highly virulent PEDV G2b strain (100 TCID50/0.1 ml). A VN titer ≥ 8 was considered indicative of the presence of PEDV-neutralizing antibodies. Levels of statistical significance are indicated as follows: *p < 0.05; ***p < 0.001; ****p < 0.0001.

earlier work, the binding of glycoprotein H7-pII protein to ND caused only a slight shift in zeta potential (from approximately –45 mV to –38 mV), and the hydrophobic regions of the H7-pII protein were thought to mediate adsorption, thereby preserving glycosylated epitopes crucial for immune recognition (28). Considering these structural similarities, it is plausible that COES1D attaches to ND nanoparticles mainly via hydrophobic interactions, rather than through electrostatic attraction or direct binding to glycans. This type of adsorption is likely to preserve the native antigenic structure of COE-S1D, potentially improving its recognition by immune cells. Thus, non-covalent coating onto ND represents an effective strategy for formulating COE-S1D:ND vaccine complexes without chemical modification. The immunogenicity of the COE-S1D:ND mixture was assessed in pregnant sows in comparison with the free COE-S1D protein. Vaccination with the COE-S1D:ND complexes elicited a stronger humoral response against PEDV than the free COE-S1D-pII formulation in pregnant sows. Intramuscular immunization of pregnant sows with the COE-S1D-pII protein and the COE-S1D: ND complexes primarily induced systemic humoral responses, as evidenced by elevated PEDV-specific IgG levels. Specifically, the sows receiving the COE-S1D:ND mixture developed a PEDVspecific IgG response with an S/P mean ratio approximately twice that observed in the free COE-S1D-pII group. Importantly, we also detected increased IgA titers in sow milk. Since the porcine placenta does not transfer antibodies during gestation, newborn piglets acquire maternal antibodies almost exclusively by ingesting colostrum and milk after birth (53). Higher concentrations of secretory IgA in maternal milk play a crucial role in protecting piglets against enteric pathogens, including PEDV (8, 54, 55). Notably, a twofold higher endpoint IgA titer was also detected in the milk of the sows vaccinated with the COE-S1D:ND mixture compared to sows immunized with the COE-S1D protein alone. These findings are in line with previous reports indicating that intramuscular immunization has been shown to elicit antigenspecific IgG responses while also promoting IgA production (56). In addition, multiple studies highlight the essential role of both IgA and IgG antibodies in safeguarding piglets against PEDV infection (57, 58). In addition, the sows vaccinated with the COE-S1D:ND mixture showed a modestly higher virus-neutralizing antibody titer relative to those immunized with the free COE-S1D-pII protein. Considering the well-established correlation between neutralizing antibody titers and vaccine efficacy documented in commercial vaccines (59), improving neutralizing antibody responses after vaccination remains an essential goal in vaccine design and development. Next, the humoral immune response against PEDV was observed in piglets born to sows vaccinated with either the COES1D-pII protein or the COE-S1D:ND complexes. Notably, higher PEDV-specific IgG antibodies were detected in piglets from sows vaccinated with the COE-S1D:ND complexes compared to those from sows vaccinated with the free COE-S1D-pII protein. In addition, piglets in the COE-S1D:ND group showed a twofold

surface chemistry that can be tailored for a wide range of applications (37). Within vaccinology, NDs present several unique benefits. Their nanoscale size is comparable to that of many bacterial and viral pathogens, enabling them to serve as both adjuvants that boost immune responses and as carriers that enhance antigen presentation (38, 39). Furthermore, the hydrophobic properties of acid-oxidized NDs facilitate strong interactions with native membrane proteins as well as soluble antigens (40). Plant-based expression systems have been widely used to produce a variety of recombinant proteins, vaccines, and bioactive compounds (17, 41, 42). Plant expression platforms using transient offer several advantages, including rapid protein accumulation, relatively consistent yields, scalability, and cost-effectiveness compared with microbial or mammalian systems (17, 41–44). However, some limitations remain. Protein expression can be variable and occasionally lower than in chemical or microbial systems (45), and downstream purification is often complicated by plant-derived compounds such as phenolics, lignin, and polysaccharides, which can interfere with chromatography and reduce product purity (46). Moreover, plant-specific glycosylation patterns may differ from those of humans and animals, potentially affecting protein activity or immunogenicity (47). Despite these challenges, transient plant-based expression remains a versatile and valuable platform, as illustrated by the successful development of plant-derived vaccines. The Newcastle disease vaccine for poultry, produced in plants, was the first to receive approval by the U.S. Department of Agriculture in 2006. Since then, vaccines against influenza, Ebola, rabies, hepatitis B, norovirus, anthrax, and rotavirus have advanced through clinical trials. Medicago’s quadrivalent influenza vaccine completed Phase 3 trials, demonstrating safety, efficacy, and strong immunogenicity in humans (48). Building on the strengths and limitations of plantbased expression platforms as well as our previous experience in expressing various recombinant proteins in plants such as hemagglutinin protein from H5N1 (49, 50), H7N9 (28), and the COE protein from PEDV (19, 20), we for the first time produced COE-S1D-pII protein in N. benthamiana via transient expression and investigated the effect of nanodiamonds on the immune response to this plant-derived protein in pigs. Here, we utilized acid-oxidized-ND as carriers to present the COE-S1D protein produced in plants from PEDV. The successful coating of COE protein onto NDs was verified by Western blot analysis across a range of protein-to-nanoparticle mass ratios. The highest adsorption efficiency was observed at a ratio of 1:24 (w/w), as confirmed by Western blot signals. Analysis by dynamic light scattering revealed a significant enlargement in particle size and a change in zeta potential in the COE-S1D:ND complexes, compared with bare ND nanoparticles. These results confirm that the COES1D protein can effectively coat the surface of ND without the need for chemical crosslinking agents. Comparable adsorption behavior has been documented, such as the binding of OVA to solid NDs without the need for additional coupling reagents (28, 51, 52). In

sows vaccinated with the COE-pII protein in the previous study (20). The neutralizing antibody titer found in piglets vaccinated with the COE-S1D mixture was quite similar to that found in piglets vaccinated with COE-ferritin, one of the ferritin nanoparticle-based vaccines in a recent study (62). As a result, incorporating ND nanoparticles markedly boosted the immunogenicity of the plantproduced COE-S1D protein. The new formulation markedly enhanced both systemic and mucosal immunity and significantly increased neutralizing antibody titers in piglets. The current formulation may provide more effective coverage against prevalent PEDV G2b strain. Various studies have demonstrated that antigens can be adsorbed onto ND nanoparticles can markedly increase humoral immune responses and immunological benefits (28, 51, 63, 64). Nanocomplexes are formed by conjugating viral proteins such as HA/H7N9 onto oxidized NDs with particle sizes from roughly 50 nm to 500 nm. These complexes significantly boosted vaccine immunogenicity: hemagglutination titers increased up to 512-fold compared to the free H7 protein, while H7-specific IgG levels in mice rose by over 15.4-fold after the second immunization (28). Similarly, negatively oxidized NDs conjugated with HA/H5N1 antigen led to higher hemagglutination titers and elevated HAspecific IgG and neutralizing antibodies in mice (51). Beyond viral proteins, NDs have also been combined with other bioactive molecules to enhance immune responses further. For instance, carboxylated NDs covalently linked to NH2-PLGA nanoparticles encapsulating fig polysaccharides (FP) formed NDs-PLGA-FP/ OVA complexes. These complexes promoted antigen uptake, increased lymphocyte proliferation, elevated expression of MHC II, CD80, and CD86, and shifted the Th1/Th2 cell balance. They also activated the IL-17 signaling pathway, resulting in higher secretion of cytokines and leading to increased OVA-specific IgG levels (65). Importantly, NDs and fluorescent NDs (FNDs) have demonstrated safety and efficacy as nonallergenic adjuvants when combined with incomplete Freund’s adjuvant (IFA). In a mouse model immunized with ovalbumin (OVA), these ND-based formulations significantly enhanced antibody production and inhibited tumor growth, maintaining suppression of lymphoma cells for over 35 days (52). The exact ways nanodiamonds (NDs) affect antigen presentation and stimulate immune cells remain unclear. While our study primarily evaluated immunogenicity, previous research provides indirect evidence for the immunostimulatory potential of NDs. NDs and nanoplatinum have been shown to activate dendritic cells in vitro, promoting CD4+ T cell proliferation and upregulation of CD25, indicative of adaptive immune activation (66). NDs also were demonstrated to trigger receptors on dendritic cells and macrophages, inducing strong antiviral-like responses while preserving cell viability (67). These observations suggest pathways for NDs to enhance antigen presentation and immune activation, yet further mechanistic work is needed. Taken together, these studies highlight the potential of NDs as versatile and biocompatible platforms for improving vaccine efficacy. Even though our data showed that the COE-S1D:ND formulation improved immunogenicity, there are a few

higher endpoint titer of COE-S1D-specific IgA antibodies and a 1.6fold higher level of PEDV-neutralizing antibodies. The presence of IgA in piglet serum further suggests effective transfer of these antibodies, contributing to systemic and mucosal immunity (60). Overall, these results suggest that the COE-S1D:ND formulation may enhance both humoral and mucosal immune responses, which are crucial for protecting newborn piglets against PEDV infection. Interestingly, the humoral immune responses against PEDV measured in 5-day-old piglets were higher than those observed in the mother sows. Before parturition, sows actively transport large amounts of IgG and IgA from the bloodstream into the mammary glands, leading to colostrum antibody concentrations several times higher than those in maternal serum. This selective transfer temporarily lowers antibody levels in the sow’s blood after farrowing. As a result, the serum concentrations of IgG, IgA, and virus-neutralizing antibodies in piglets can temporarily exceed those in the sow’s serum and milk at the same time point, especially within the first few days postpartum. Five-day-old piglets retain high levels of antibodies absorbed earlier from colostrum, so their serum IgG, IgA, and neutralizing antibody levels can remain higher than those measured in the sow’s serum and milk sampled concurrently. Our observations agree with prior research indicating that IgG and IgA concentrations in piglets generally follow similar trends to those in sow serum and colostrum (53). Although the serum antibody levels in 5-day-old piglets can temporarily exceed those measured in the sows immediately after farrowing, the overall humoral responses in piglets still reflect the antibody status of their mothers. Several studies found that high levels of neutralizing antibodies play a crucial role in safeguarding against PEDV infections (21, 61). In the present study, we aimed to develop an improved formulation capable of eliciting stronger immune responses, particularly neutralizing activity against PEDV G2b, which is the predominant circulating strain in Vietnam. When comparing the neutralizing antibody titers against PEDV, piglets born to sows vaccinated with the free COE-S1D protein showed approximately 3.8-fold higher titers than the titer reported in piglets born to sows vaccinated with the COE-pII protein in the previous study (20), in which the COE-pII protein elicited protective immunity in piglets against PEDV G2a. Furthermore, when comparing the immunogenicity of COE-pII protein and COE-S1D-pII protein in piglets, we observed that piglets immunized with COE-S1D-pII protein produced stronger COE-specific IgG, IgA, and neutralizing antibody responses against PEDV G2a than those vaccinated with COE-pII protein (data not shown). These results indicate that COES1D-pII could represent a stronger correlate of protection, underscoring its promise for developing more effective vaccines against PED in Vietnam. In another experiment, piglets immunized with 50 μg of COE-S1D-pII protein developed COE-S1D-specific IgG and IgA, as well as neutralizing antibodies against PEDV, comparable to those induced by a commercial PEDV vaccine after two immunizations (Supplementary Figure 1). In addition, piglets born to sows vaccinated with the COE-S1D:ND mixture showed approximately 6.2-fold higher titers than the titers in piglets born to

limitations worth noting. It is important to note that PEDV causes the highest mortality in piglets younger than one week of age (3). While our main focus was on the immune responses of piglets born to sows immunized with the COE-S1D-pII protein or the COES1D:ND complexes, the limited number of sows constrained the statistical power of our analyses. In our study, each sow produced five piglets, and the immune response data from these piglets provided sufficient statistical power for meaningful analysis. Moreover, the use of a limited number of sows in immunization trials was reported in similar studies (2, 36), supporting the feasibility of our experimental design. The main constraints contributing to this limitation were the high costs and logistical challenges associated with maintaining and immunizing pregnant sows and ethical considerations in using large animals. Additionally, at the time of the study, the widespread outbreak of African swine fever across many regions of Vietnam made it particularly difficult to recruit herds that were both healthy and PEDV-negative. Moreover, due to the high cost of long-term monitoring, we could not extend the follow-up period in this study, which is important to determine the duration of protection conferred by the vaccine. Here, we did not assess cellular immune responses, such as T cell activation. Nevertheless, our previous research showed that another plant-based COE-pII protein could induce IFN-g responses in both sows and their piglets (20). Additionally, challenge experiments were not conducted to directly evaluate protective efficacy, including survival or mortality after exposure to highly virulent PEDV strains. Nevertheless, the neutralizing antibody titers observed in piglets from sows immunized with the COE-S1D-pII protein and the COES1D:ND complexes were higher than those previously shown to confer piglet protection, suggesting promising vaccine potential. Future studies should involve larger cohorts of sows and incorporate assessments of long-term immunity, cellular immune responses, and challenge experiments to evaluate this nanovaccine candidate’s protective potential fully. Moreover, to enable largescale production of COE-S1D-pII protein, further optimization of the purification process is necessary, using methods suitable for scalable manufacturing. These efforts aim to establish a nanovaccine candidate capable of inducing broader and longer-lasting immunity against PEDV strains circulating in Vietnam.

Data availability statement The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement The animal study was approved by The Ethics Committee of the Institute of Biology, Vietnam Academy of Science and Technology (VAST), Hanoi. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions TH: Software, Writing – original draft, Writing – review & editing, Validation, Data curation, Visualization, Formal Analysis. HT: Methodology, Writing – review & editing. PN: Methodology, Writing – review & editing. HB: Methodology, Writing – review & editing. HN: Writing – review & editing, Methodology. TL: Writing – review & editing. MP: Methodology, Writing – review & editing. WH: Methodology, Writing – review & editing. DN: Writing – review & editing, Methodology. HC: Writing – review & editing. NP: Resources, Funding acquisition, Project administration, Supervision, Conceptualization, Writing – review & editing. HH: Project administration, Conceptualization, Funding acquisition, Supervision, Resources, Writing – review & editing.

📖 中文全文 Chinese Full Text

中文

# 纳米金刚石配制的植物蛋白诱导仔猪对猪流行性腹泻病毒的强免疫力

**类型** 原创研究 **发表日期** 2025年9月19日 **DOI** 10.3389/fimmu.2025.1674222 **开放获取** **编辑** Abel A. Ramos Vega,墨西哥国家理工学院(IPN) **审稿人** Victor H. Leyva-Grado,美国AuroVaccines公司 Mohammad Sadegh Taghizadeh,伊朗设拉子大学 **通讯作者** Ngoc Bich Pham(pbngoc@ib.ac.vn) Hang Thu Thi Hoang(hanghtt@ib.ac.vn) **收稿日期** 2025年7月27日 **接受日期** 2025年9月2日 **发表日期** 2025年9月19日

**引用格式** Ho TT, Tran HT, Nguyen PMT, Bui HT, Nguyen HTT, Le TBT, Pham MD, Hsiao WW-W, Nguyen DH, Chu HH, Pham NB and Hoang HTT (2025). 纳米金刚石配制的植物蛋白诱导仔猪对猪流行性腹泻病毒的强免疫力. *Front. Immunol.* 16:1674222. doi: 10.3389/fimmu.2025.1674222

**版权声明** © 2025 Ho, Tran, Nguyen, Bui, Nguyen, Le, Pham, Hsiao, Nguyen, Chu, Pham and Hoang. 本文为根据知识共享署名许可协议(CC BY)条款分发的开放获取文章。在其他论坛使用、分发或复制本文须注明原作者和版权所有者,并注明发表于本期刊,且符合公认的学术规范。任何不符合上述条款的使用、分发或复制行为均不被允许。

---

Thuong Thi Ho¹, Hoai Thu Tran¹, Phuong Minh Thi Nguyen¹, Huyen Thi Bui¹, Hien Thu Thi Nguyen¹, Thao Bich Thi Le¹, Minh Dinh Pham¹, Wesley Wei-Wen Hsiao², Dai Huu Nguyen³, Ha Hoang Chu¹⁴, Ngoc Bich Pham¹⁴* 和 Hang Thu Thi Hoang¹⁴*

¹ 越南科学技术研究院生物学研究所,越南河内 ² 国立台湾科技大学化学工程系,中国台湾台北 ³ CNC兽医药品贸易与生产股份公司,越南河内 ⁴ 越南科学技术研究院研究生院,越南河内

猪流行性腹泻病毒(PEDV)仍然是猪群中的主要传染威胁,尤其危及仔猪。COE和S1D结构域已被鉴定为适用于设计亚单位疫苗的关键抗原。纳米金刚石(NDs)因其生物相容性大、比表面积大和表面可修饰性而作为新型载体受到关注,可用于改进重组蛋白疫苗。在本研究中,我们在本氏烟(*Nicotiana benthamiana*)中瞬时表达了含有GCN4pII基序的COE-S1D融合蛋白(COE-S1D-pII)。随后将重组蛋白与纳米金刚石以不同质量比混合,形成COE-S1D:ND复合物。SDS-PAGE和Western blot分析确定最佳比例为1:24(w/w)。对这些复合物进行了额外的粒径、zeta电位和形态学表征。随后,我们在妊娠母猪及其仔猪中评估了COE-S1D:ND复合物(1:24, w/w)的免疫应答,并与游离COE-S1D-pII蛋白诱导的应答进行了比较。加强免疫后,COE-S1D:ND混合物显著增强了仔猪中PEDV特异性IgG和COE-S1D特异性IgA水平以及中和抗体滴度,通过ELISA和病毒中和试验测定。总体而言,结果强调了ND纳米颗粒可增强全身和黏膜免疫力,支持将植物源COE-S1D-pII蛋白与纳米金刚石结合作为抗PEDV的新一代亚单位疫苗候选物的潜力。

**关键词:** 纳米金刚石、COE-S1D-pII蛋白、PEDV、免疫应答、疫苗、仔猪

---

## 引言

猪流行性腹泻病毒(PEDV)是一种RNA病毒,分类于冠状病毒科(Coronaviridae)α冠状病毒属(Alphacoronavirus)(1)。PEDV是引起猪严重水样腹泻的主要病毒性病原体(2)。尽管PEDV可感染任何年龄的猪,但对哺乳仔猪的危害尤为严重,可引起急性肠道疾病,死亡率高达80-100%(3)。因此,猪流行性腹泻(PED)仍然是全球养猪业面临的重大传染威胁,尤其在亚洲,反复暴发的疫情持续造成重大经济损失(4, 5)。经典基因群(G1)PEDV毒株通常与轻度或低致病性感染相关,而致病性更强的基因群2(G2)毒株——包括G2a和G2b亚群——与导致哺乳仔猪死亡率接近100%的疫情暴发有关(6)。在越南,大规模PEDV疫情主要由G2毒株引起(7)。尽管持续努力,目前仍缺乏能有效保护免疫学上未接触过PEDV的猪只的疫苗,这凸显了应对PED疫情的持续挑战(8)。

在PEDV的四种结构蛋白中,刺突(S)蛋白对促进病毒进入宿主细胞至关重要,是诱导中和抗体应答的主要免疫原(9)。由于这些关键功能,S蛋白被认为是亚单位疫苗设计的主要靶标。结构上,S蛋白包含两个不同的结构域:S1结构域(氨基酸1-789)和S2结构域(氨基酸790-1383)(10)。在S1结构域内,已鉴定出两个主要的中和表位:COE表位(氨基酸499-638)和新近鉴定的S1D区域(氨基酸636-789)。这些表位已被证明可刺激针对PEDV的强中和抗体应答,使其成为开发下一代亚单位疫苗的有吸引力的候选物(11, 12)。

迄今为止,PEDV的COE和S1D蛋白已在多种异源系统中成功表达为与不同基序的融合蛋白,包括大肠杆菌(*Escherichia coli*)(13)、酵母(14)、哺乳动物细胞(15)和植物(16)。在这些平台中,基于植物的表达系统——特别是通过农杆菌浸润的瞬时表达——因其快速生产、可扩展性和成本效益而成为有前景的策略(17, 18)。在我们之前的研究中,COE蛋白变体在本氏烟中作为与GCN4pII基序(pII)的融合构建体被瞬时表达,其免疫原性在动物模型中得到了验证(19, 20)。值得注意的是,源自越南高致病性PEDV G2a毒株的COE蛋白在与pII基序融合后(命名为COE/G2a-pII),在免疫妊娠母猪所产仔猪中诱导了针对PEDV G2a毒株的保护性免疫应答(20)。然而,在这些仔猪中检测到的中和抗体滴度仍不理想,需要提高以确保更强和更广泛的保护,特别是针对越南流行的PEDV G2b毒株。尽管单独血清中的抗体不足以提供完全保护以抵御PEDV感染,但血清中中和抗体水平与对PEDV的抗性增强相关(21)。这凸显了研究可触发更强中和应答以实现更广泛保护的替代抗原或抗原组合的重要性。在这方面,扩展的COE-S1D片段——包含COE区域和相邻的S1D中和表位——提供了扩大抗原覆盖范围的潜力。迄今为止,尚未有研究报道COE-S1D蛋白(氨基酸499-789)与pII基序融合后在植物中的瞬时表达,也未见其在动物模型中的免疫原性数据。为了进一步改善这些植物源COE-S1D-pII蛋白的免疫原性,我们研究了将纳米金刚石(ND)作为新型纳米颗粒佐剂和递送载体的潜力。

在设计将免疫应答导向表位的现代蛋白亚单位疫苗方面,纳米颗粒已被证明具有不可替代的价值。其作为抗原和药物载体或佐剂的广泛应用源于其降低副作用、增加制剂稳定性和强烈促进体液免疫应答的能力(22, 23)。NDs结合了若干吸引人的特性,如优异的生物相容性、易于修饰的表面化学性质、高抗原载量能力以及与其他碳纳米材料相比更低的毒性(24-27)。此外,将纳米颗粒作为疫苗佐剂已被证明可增强免疫应答(28, 29)。

在本研究中,我们通过瞬时表达在本氏烟中生产了COE-S1D蛋白。我们旨在探索加入NDs是否能增强植物源COE-S1D-pII蛋白对PEDV的免疫原性。我们在妊娠母猪及其仔猪中评估了免疫应答,以更好地代表目标宿主环境。通过比较COE-S1D-pII:ND制剂(简称COE-S1D:ND)与游离植物源COE-S1D-pII蛋白诱导的免疫应答,我们旨在确定纳米金刚石的佐剂潜力。总体而言,我们的结果表明,COE-S1D:ND复合物对高致病性PEDV G2b毒株诱导的免疫应答显著强于游离COE-S1D蛋白。这凸显了将纳米金刚石作为纳米颗粒佐剂用于PEDV亚单位疫苗开发的前景。

---

## 方法

### PEDV植物源COE-S1D-pII蛋白的生产与表征

选择PEDV毒株NAVET/PEDV/PS6/2010(基因型G2a)S蛋白氨基酸499-789对应的编码序列以构建COE-S1D构建体。核苷酸序列经密码子优化以在本氏烟中高效表达。优化后的片段与一系列功能元件框内融合,包括:(i)N端6×His标签,用于亲和纯化和检测;(ii)GCN4pII基序,用于促进三聚化;(iii)KDEL信号,用于蛋白在内质网中的积累。该合成表达盒由花椰菜花叶病毒(CaMV)35S启动子驱动,并插入pRTRA载体骨架中。随后将组装好的表达盒亚克隆至双元载体pCB301中,用于根癌农杆菌(*Agrobacterium tumefaciens*)介导的通过真空浸润在本氏烟中进行瞬时表达,遵循前述程序(19)。

农杆菌浸润后五天,收获浸润的本氏烟叶片组织,立即在-80°C冷冻用于下游处理。通过SDS-PAGE和Western blot检测和半定量本氏烟叶片中COE-S1D-pII蛋白的表达。印迹使用抗His标签单克隆抗体或用商品化PEDV AJ1102毒株疫苗(科兴,武汉科前生物)免疫的猪血清作为一抗,分别以山羊抗小鼠IgG-HRP(Invitrogen)或山羊抗猪IgG(H+L)-HRP(SouthernBiotech)作为二抗。通过与H5N1特异性ScFv蛋白(30)的标准曲线比较条带强度,使用ImageQuant TL 8.0软件(Cytiva)和Amersham™ Imager 680对信号进行可视化和定量。

重组COE-S1D-pII蛋白通过固定化金属亲和层析(IMAC)和尺寸排阻层析(SEC)从植物生物质中提取和纯化,如前所述(20)。纯化蛋白组分在1× PBS(pH 7.4)中配制成50%(v/v)甘油溶液,保存于-20°C以维持结构稳定性和抗原性。此外,使用BS3(双[磺基琥珀酰亚胺基]辛二酸酯)化学交联评估纯化的COE-S1D-pII蛋白的多聚状态(31)。简言之,1 μg COE-S1D-pII蛋白与5 mM BS3在室温反应30分钟,然后加入Tris-HCl缓冲液(pH 8.0)至50 mM终止反应。产物在还原条件下通过4-10% SDS-PAGE分离,使用抗His标签抗体通过Western blot检测。

使用SWISS-MODEL(32)基于序列相似性选择的模板对COE-S1D蛋白的三级结构进行建模。通过服务器提供的GMQE和QMEAN评分评估模型质量。

### COE-S1D:ND复合物的制备与表征

为获得均匀的ND悬浮液,将表面氧化的纳米金刚石(NDs)在去离子水中超声分散至浓度为10 mg/mL。然后将COE-S1D-pII蛋白以1:6、1:12、1:24、1:36和1:48的质量比加入磷酸盐缓冲盐水(1× PBS, pH 7.4)中的ND悬浮液。为促进蛋白在ND表面的吸附,将混合物在冰上轻轻超声5分钟。孵育后,样品以13,000 rpm离心15分钟。沉淀用去离子水轻轻洗涤两次以去除未结合的蛋白,随后重悬于PBS中用于进一步分析。使用Bradford法测定蛋白结合效率,通过监测一周内颗粒大小和保留蛋白含量评估复合物稳定性。

按照前述方案(33)通过SDS-PAGE和Western blot分析对复合物进行表征。样品与4× SDS-PAGE上样缓冲液混合,在95°C加热20分钟变性。在12% SDS-PAGE凝胶上电泳后,将蛋白在35 V下过夜转移至PVDF膜。膜在PBS(pH 7.4)中5%牛奶中封闭2小时,与抗6×His标签抗体(Invitrogen)孵育2小时,然后与山羊抗小鼠IgG-HRP(Invitrogen)孵育1小时。使用DAB(Sigma)在0.05 M Tris-HCl(pH 7.2)中显色。使用Amersham™ Imager 680、ImageQuant TL 8.0(Cytiva)和ImageJ进行信号检测和定量。

按照前述方案(33)对COE-S1D:ND复合物的粒径分布、多分散指数(PDI)和zeta电位进行表征。将各样品用去离子水稀释至终浓度50 mg/mL,在37°C下测量三次。使用Zetasizer Nano ZS(Malvern Panalytical)评估流体动力学直径测量值,使用Horiba SZ-100分析仪测定zeta电位。使用在120 kV下操作的JEOL 1400 Flash显微镜进行透射电子显微镜(TEM)形态学表征,以验证结构完整性。

### 表面氧化NDs的制备

为引入含氧官能团,将商品化金刚石粉末(Diamond Innovations, USA)用浓硫酸和硝酸的3:1(v/v)混合物(H₂SO₄:HNO₃)处理进行氧化。氧化反应使用Model Discover微波系统(CEM)在约100°C和100 W下进行3小时,遵循报道的程序(28)。反应后,在收集纳米金刚石之前小心稀释残余酸。所有程序均在化学通风橱中进行以最小化暴露于二氧化氮(NO₂)。在收集NDs之前小心稀释残余酸。

### 猪免疫

动物实验经越南科学技术研究院(VAST)生物学研究所伦理委员会批准。所有程序符合"3R"原则,并遵守欧洲共同体理事会关于实验动物保护和使用的指令86/609/EEC。猪只由兽医饲养和密切监测,以最小化实验过程中的应激、疼痛和不适。免疫前两周,采集妊娠母猪血液样本用于检测PEDV-IgG、IgA特异性抗体和PEDV中和抗体。入组六只缺乏PEDV-IgG、IgA抗体和中和抗体的妊娠母猪。纯化的COE-S1D-pII蛋白(150 μg/剂)、COE-S1D:ND混合物(每剂含150 μg COE-S1D蛋白和3.6 mg ND)或PBS与ND混合物(3.6 mg/剂)与Emulsigen®-D佐剂(MVP)以8:2比例乳化。在妊娠约80天时,母猪在第0天和第14天颈部肌肉免疫。免疫后第0天和第35天采集母猪血液样本,免疫后第35天采集奶样。允许免疫母猪或PBS:ND对照母猪所产仔猪(n=5)吸吮母乳并与母猪同养。在5日龄时采集所有仔猪的血液样本用于进一步分析。所有血清和奶样保存于-20°C直至通过ELISA测定PEDV特异性IgG和IgA抗体应答,以及测定PEDV中和抗体滴度。

### 通过ELISA评估PEDV特异性IgG抗体

使用商品化ELISA试剂盒(INgezim PEDV 11.PED.K.1/5, Eurofins INGENASA)检测母猪血清和仔猪血清中的PEDV特异性IgG。检测前将仔猪血清1:100稀释。S/P(样品/阳性)比计算如下:(样品OD - 阴性对照OD)/(阳性对照OD - 阴性对照OD)。S/P值超过0.35的样品被认为PEDV特异性IgG阳性。

### 通过ELISA评估COE-S1D特异性IgA抗体

按照前述方案(30)通过间接ELISA检测母猪奶和仔猪血清中COE特异性IgA水平,略有调整。简言之,使用SEC纯化的COE-S1D蛋白(每孔100 ng,1 ng/μL)在PBS(pH 7.4)中于4°C过夜包被96孔板。然后将板在PBS中5%脱脂奶溶液中孵育。为检测IgA,将奶和血清样品以1:10至1:640的系列稀释度加入。然后将板在室温孵育2小时,用含0.05% Tween 20的PBS洗涤三次,随后用阻断缓冲液1:5000稀释的HRP偶联山羊抗小鼠IgA(SouthernBiotech)处理。与TMB底物孵育15分钟后,加入1 M H₂SO₄终止反应。在450 nm处测量吸光度。

### 病毒中和抗体试验

为评估猪血清中的中和抗体,基于文献(33)描述的方法进行病毒中和试验,略有修改。血清样品在56°C热灭活30分钟,然后进行系列稀释。将各稀释度与100 TCID₅₀/0.1 mL的高致病性越南PEDV G2b毒株混合,在37°C孵育1小时以允许抗体-病毒相互作用。然后将混合物加入汇合的Vero细胞单层,在37°C再放置1小时,然后用PBS轻轻洗涤以去除未结合的病毒。孵育后,细胞培养物接受含胰蛋白酶的新鲜α-MEM培养基,在CO₂培养箱中于37°C保持六天。中和抗体滴度评估为完全阻断细胞单层中出现细胞病变效应的最大血清稀释度。

### 统计分析

使用GraphPad Prism 8.0版中的Mann-Whitney检验进行数据分析。结果以平均值及其对应标准差(SD)报告。组间统计学显著性接受p值低于0.05。显著性水平表示如下:*p < 0.05;**p < 0.01;***p < 0.001;****p < 0.0001。

---

## 结果

### PEDV植物源COE-S1D-pII蛋白的生产与表征

为实现在本氏烟中表达COE-S1D-pII蛋白,构建了含有目标基因的植物表达载体(图1A)。随后通过转化将该重组载体导入根癌农杆菌,使表达盒能够递送至植物系统中。通过使用抗His抗体进行Western blot分析检测本氏烟叶片中COE-S1D-pII蛋白的积累。SDS-PAGE和Western blot结果证实了COE-S1D-pII抗原在烟草叶片中的成功表达,膜上可见表观分子量大于55 kDa的条带。重组单体COE-S1D-pII抗原的理论分子量计算为38.2 kDa。然而,实验观察到的单体COE-S1D抗原的分子量大于55 kDa。COE-S1D-pII抗原的理论分子量与观察值之间的差异可能归因于糖基化修饰,这可能影响SDS-PAGE期间抗原的迁移和分离。使用NetNGlyc 1.0进行计算机分析,在COE-S1D区域鉴定出六个预测的N-连接糖基化位点。这些N-聚糖预计会增加表观分子量并延缓SDS-PAGE中的电泳迁移。这一解释与显示PEDV刺突蛋白被N-糖基化的已发表数据一致(33-35)。重要的是,生化研究表明PNGase F(而非O-糖苷酶)增加了重组PEDV S1的电泳迁移率,证实了主要的N-连接聚糖及其对表观分子量的影响(36)。总之,这些发现加上我们对COE-S1D-pII中六个N-糖基化位点的预测,可能为理论分子量与观察值之间的差异提供了机制性解释。在非转基因本氏烟植物的叶提取物中未检测到COE-S1D-pII抗原。通过Western blot半定量分析本氏烟叶片中重组COE-S1D抗原的积累水平。使用特定ScFv H5条带的浓度和信号强度(27)在用Amersham™ Imager 680(Cytiva)采集图像后,使用ImageQuant TL软件(Cytiva)构建标准曲线。半定量分析显示,COE-S1D蛋白在烟草叶片中的积累约为115 mg/kg鲜叶,占总可溶性蛋白的1.95%(图1B)。该积累水平与COE蛋白相当(20)。

此外,还使用用含PEDV AJ1102毒株的科兴(武汉科前生物)疫苗免疫的猪血清检测了本氏烟叶片中重组COE-S1D-pII蛋白的表达(图1C)。图1C中的Western blot结果显示膜上有一条与理论计算一致的分子量条带,约55 kDa。这一发现表明,在本氏烟叶片中产生的COE-S1D-pII蛋白保留了与天然PEDV抗原相似的抗原特性。

### COE-S1D-pII蛋白的纯化与寡聚状态表征

首先通过IMAC纯化COE-S1D-pII蛋白。使用SDS-PAGE分析IMAC纯化后各组分中COE-S1D-pII蛋白的存在,随后进行考马斯蓝染色,并通过Western blot分析进一步确认(图2A, B)。结果表明,流穿(FT)和洗涤(W)组分中不存在COE-S1D-pII蛋白。纯化的COE-S1D-pII抗原主要在洗脱(E)组分中检测到。

将IMAC纯化的COE-S1D-pII蛋白进行SEC和交联分析以评估其寡聚特征。使用BS3交联评估COE-S1D蛋白的寡聚状态。SDS-PAGE分析结合考马斯蓝染色和Western blot显示,当BS3存在时出现大于250 kDa的条带(图2C)。结合SEC分析结果,这表明COE-S1D蛋白在天然条件下主要形成寡聚体。

此外,SEC纯化结果结合Western blot分析表明,COE-S1D-pII蛋白在组分16-24中检测到,对应于约440-669 kDa的分子量范围(图2D, E)。使用SWISS-MODEL基于PEDV S糖蛋白的冷冻电子显微镜(cryo-EM)结构(PDB ID: 6VV5.1.A)作为模板构建COE-S1D-pII蛋白的三级结构(图2F)。该模板与COE-S1D蛋白具有95.65%的序列同一性,支持了模型的准确性。预测模型产生0.75的GMQE评分和0.80 ± 0.05的QMEANDisCo总体评分,表明整体质量良好且结构可靠,可用于下游分析。所得模型预测COE-S1D-pII蛋白形成同源三聚体,与天然PEDV刺突糖蛋白的三聚组织一致。

### COE-S1D:ND复合物的表征

通过在冰上超声处理COE-S1D-pII蛋白和ND颗粒的物理混合物制备COE-S1D:ND复合物,质量比各不相同(1:6、1:12、1:24、1:36和1:48)。为确定COE-S1D-pII蛋白与ND表面结合效率最高的比例,进行了Bradford法、SDS-PAGE和Western blot分析(图3A, B)。Bradford法和Western blot结果证实了COE蛋白成功吸附到ND上。使用ImageJ软件分析显示,将COE-S1D-pII蛋白与ND以1:6、1:12和1:24(w/w)的质量比混合,蛋白吸附效率分别从39%增加到57%,再增加到85.3%。然而,进一步增加ND量至1:36和1:48(w/w)的比例并未显著提高吸附水平。因此,选择1:24(w/w)比例用于后续实验。

ND的流体动力学直径显示平均流体动力学直径为200.2 nm,而COE-S1D:ND复合物稍大,为433.6 nm(图3C, D)。在用COE-S1D-pII蛋白(pI 5.6,在pH 7.4下带负电)包被ND颗粒后,复合物的zeta电位从-77.5 mV增加到-48.2 mV(表1)。这一变化可能表明带正电荷的残基(如Lys和Arg)吸附到ND表面,部分中和其表面电荷,而复合物由于蛋白的净负电荷仍整体带负电。复合物形成过程中发生的粒径和zeta电位变化表明COE-S1D-pII蛋白吸附到ND表面。

此外,COE-S1D:ND复合物显示出比单独ND更高的多分散指数(PDI = 0.251对比PDI = 0.127),表明复合物形成后颗粒大小变化范围更广(表1)。这些观察表明蛋白分子在ND表面部分聚集和/或非均质吸附。然而,最终PDI保持在0.3以下,表明COE-S1D:ND复合物维持了适合疫苗应用的可接受水平的胶体稳定性。

通过TEM评估COE-S1D:ND复合物的形态学和结构特征(图3E)。TEM图像显示COE-S1D:ND具有不规则形态。观察到的颗粒大小和形状异质性可能源于蛋白吸附水平的差异或部分聚集。此外,TEM观察表明单个COE-S1D蛋白分子可能桥接两个不同的纳米颗粒,导致显微照片中出现聚集外观。总之,这些结果表明COE-S1D-pII蛋白有效地附着在ND表面,形成了预期的COE-S1D:ND复合物。

**表1 ND和COE-S1D:ND复合物的理化特性**

| 结构 | Zeta电位 (mV) | 流体动力学粒径 (nm) | PDI | |------|---------------|-------------------|-----| | ND | -77.5 | 200.2 | 0.127 | | COE-S1D:ND | -48.2 | 433.6 | 0.25 |

### COE-S1D:ND混合物在妊娠母猪中诱导比游离COE-S1D-pII蛋白更强的针对PEDV的体液和黏膜应答

根据图4A所示的免疫方案评估了COE-S1D-pII蛋白和COE-S1D蛋白与ND混合物(1:24, w/w)在妊娠母猪中的免疫原性。免疫后第35天(pi),在用COE-S1D-pII免疫的母猪血清中检测到PEDV特异性IgG抗体,S/P平均比值为1.03(图4B)。同时,接种COE-S1D:ND的母猪显示出更高的PEDV特异性IgG应答,平均S/P比值为2.04。然而,两组间PEDV特异性IgG抗体的差异无统计学意义(p = 0.293 > 0.05)。相比之下,接受PBS:ND的对照母猪血清中未检测到PEDV特异性IgG抗体。

同样,在第35天pi,在用COE-S1D-pII疫苗接种的母猪奶中检测到COE-S1D特异性IgA抗体,平均终点IgA滴度为60(图4C)。相比之下,用COE-S1D:ND免疫的母猪表现出2倍高的IgA应答,达到平均终点IgA滴度126。两组间COE-S1D特异性IgA抗体的差异具有统计学意义(p = 0.0014 < 0.01)。相比之下,PBS:ND对照母猪血清中未检测到COE-S1D特异性IgA抗体。

使用病毒中和试验测定针对高致病性PEDV G2b毒株的中和抗体滴度。在免疫后第35天(pi),用COE-S1D-pII免疫的母猪产生了20的平均病毒中和滴度(图4D),而接种COE-S1D:ND的母猪显示稍高的VN平均滴度24。然而,两组间中和抗体滴度的差异无统计学意义(p = 0.8108 > 0.05)。相比之下,PBS:ND对照母猪血清中未检测到针对PEDV的中和抗体。

总体而言,这些发现表明,与单独用COE-S1D-pII蛋白免疫相比,用COE-S1D:ND接种在妊娠母猪中诱导了更强的体液和黏膜免疫应答。特别是,在COE-S1D:ND组中观察到IgA水平的统计学显著增加。尽管COE-S1D:ND组的IgG和中和抗体滴度趋于更高,但差异无统计学意义。

# 翻译

## COE-S1D:ND复合物在诱导仔猪体液免疫和黏膜免疫方面优于COE-S1D蛋白

由于接种母猪初乳和乳汁中的抗体可通过哺乳传递给仔猪,因此采用ELISA和病毒中和试验评估了后代的被动免疫水平。在接种COE-S1D-pII的母猪所产5日龄仔猪血清中检测到了PEDV特异性IgG抗体。接种COE-S1D-pII的母猪所产仔猪血清中检测到PEDV特异性IgG抗体,S/P平均比值为1.41。与此同时,接种COE-S1D:ND的母猪所产仔猪表现出更高的PEDV特异性IgG应答,S/P平均比值达到2.39。两组之间PEDV特异性IgG抗体的差异具有统计学意义(p = 0.0218 < 0.05)。相反,接种PBS:ND的对照母猪所产仔猪血清中未检测到PEDV特异性IgG抗体(图5A)。

同样,接种COE-S1D-pII的母猪所产5日龄仔猪血清中含有高水平的COE-S1D特异性IgA抗体,平均终点IgA效价为120。相比之下,接种COE-S1D:ND的母猪表现出2.3倍更高的IgA应答,平均终点IgA效价达到272。两组之间COE-S1D特异性IgA抗体的差异具有统计学意义(p = 0.0006 < 0.001)。相反,PBS:ND对照仔猪血清中未检测到COE-S1D特异性IgA抗体(图5B)。

在这些5日龄仔猪血清中还鉴定出针对高致病性PEDV G2b毒株的中和抗体。接种COE-S1D-pII的母猪所产仔猪的中和效价为30.8,而接种COE-S1D:ND的母猪所产仔猪的VN平均效价高出1.6倍,达到49.6。两组之间中和抗体的差异具有统计学意义(p = 0.0431 < 0.05)。相反,PBS:ND对照仔猪血清中未检测到针对PEDV的中和抗体(图5C)。

综上所述,这些结果证明PEDV特异性IgG、COE特异性IgA和中和抗体通过初乳和乳汁从免疫母猪成功被动转移至仔猪。此外,接种COE-S1D:ND复合物的母猪所产仔猪的抗体应答始终强于接种COE-S1D-pII蛋白的母猪所产仔猪。

## 讨论

纳米金刚石(NDs)属于一类碳基纳米材料,其特征为sp³晶格结构,该结构赋予天然金刚石卓越的硬度和绝缘性能。除物理特性外,纳米金刚石在生物医学研究中因其优异的生物相容性、体内稳定性以及可灵活调控的表面化学性质而备受重视(37)。在疫苗学领域,NDs具有若干独特优势。其纳米级尺寸与许多细菌和病毒病原体相当,使其既能作为增强免疫应答的佐剂,又能作为增强抗原呈递的载体(38, 39)。此外,酸氧化NDs的疏水性有助于与天然膜蛋白及可溶性抗原产生强相互作用(40)。

植物表达系统已被广泛用于生产多种重组蛋白、疫苗和生物活性化合物(17, 41, 42)。利用瞬时表达的植物表达平台具有若干优势,包括蛋白积累快速、产量相对稳定、可扩展性强,且与微生物或哺乳动物系统相比具有成本效益(17, 41–44)。然而,仍存在一些局限性。蛋白表达可能不稳定,有时低于化学或微生物系统(45),且下游纯化常受植物来源化合物(如酚类、木质素和多糖)的干扰,这些化合物会影响层析效果并降低产品纯度(46)。此外,植物特异性糖基化模式可能与人类和动物不同,可能影响蛋白活性或免疫原性(47)。尽管存在这些挑战,瞬时植物表达仍然是一个多功能且有价值的平台,植物源疫苗的成功开发即为例证。首个获得美国农业部(2006年)批准的植物源新城疫疫苗用于家禽。此后,针对流感、埃博拉、狂犬病、乙型肝炎、诺如病毒、炭疽和轮状病毒的疫苗已进入临床试验阶段。Medicago的四价流感疫苗已完成III期临床试验,证明其在人类中具有良好的安全性、效力和强免疫原性(48)。基于植物表达平台的优势和局限性,以及我们此前在植物中表达多种重组蛋白的经验,如来自H5N1(49, 50)、H7N9(28)的血凝素蛋白以及来自PEDV的COE蛋白(19, 20),我们首次通过瞬时表达在本氏烟(*N. benthamiana*)中生产了COE-S1D-pII蛋白,并研究了纳米金刚石对该植物源蛋白在猪体内免疫应答的影响。在此,我们利用酸氧化NDs作为载体来呈递PEDV植物源COE-S1D蛋白。通过Western blot分析在不同蛋白-纳米粒子质量比范围内验证了COE蛋白在NDs上的成功包被。在1:24(w/w)的比例下观察到最高吸附效率,Western blot信号证实了这一点。动态光散射分析显示,与裸ND纳米粒子相比,COE-S1D:ND复合物的粒径显著增大,zeta电位发生变化。这些结果证实COE-S1D蛋白可在无需化学交联剂的情况下有效包被ND表面。已有类似的吸附行为报道,如OVA在无需额外偶联试剂的情况下与固体NDs的结合(28, 51, 52)。在早期工作中,H7-pII糖蛋白与ND的结合仅引起zeta电位的轻微变化(从约–45 mV变为–38 mV),H7-pII蛋白的疏水区域被认为介导了吸附作用,从而保留了免疫识别所必需的表位(28)。考虑到这些结构相似性,COE-S1D可能主要通过疏水相互作用而非静电吸引或与聚糖的直接结合附着于ND纳米粒子。这种吸附方式可能保留COE-S1D的天然抗原结构,从而潜在改善免疫细胞对其的识别。因此,非共价包被到ND上代表了在不进行化学修饰的情况下配制COE-S1D:ND疫苗复合物的有效策略。

在妊娠母猪中评估了COE-S1D:ND混合物的免疫原性,并与游离COE-S1D蛋白进行了比较。与游离COE-S1D-pII制剂相比,COE-S1D:ND复合物接种在妊娠母猪中诱导了更强的针对PEDV的体液免疫应答。妊娠母猪肌肉注射COE-S1D-pII蛋白和COE-S1D:ND复合物主要诱导了系统性体液免疫应答,PEDV特异性IgG水平升高即为证据。具体而言,接受COE-S1D:ND混合物的母猪产生的PEDV特异性IgG应答S/P平均比值约为游离COE-S1D-pII组的两倍。重要的是,我们还在母猪乳汁中检测到IgA效价升高。由于猪胎盘在妊娠期间不传递抗体,新生仔猪几乎完全通过出生后摄入初乳和乳汁获得母源抗体(53)。乳汁中较高浓度的分泌型IgA在保护仔猪抵抗肠道病原体(包括PEDV)方面发挥关键作用(8, 54, 55)。值得注意的是,接种COE-S1D:ND混合物的母猪乳汁中检测到的终点IgA效价也较接种COE-S1D蛋白的母猪高出两倍。这些发现与先前报道一致,即肌肉注射免疫已被证明可在诱导抗原特异性IgG应答的同时促进IgA产生(56)。此外,多项研究强调了IgA和IgG抗体在保护仔猪抵抗PEDV感染中的重要作用(57, 58)。此外,接种COE-S1D:ND混合物的母猪与接种游离COE-S1D-pII蛋白的母猪相比,显示出略高的病毒中和抗体效价。考虑到中和抗体效价与疫苗效力之间的良好相关性已在商业疫苗中得到充分证实(59),提高接种后的中和抗体应答仍是疫苗设计和开发的重要目标。

接下来,在接种COE-S1D-pII蛋白或COE-S1D:ND复合物的母猪所产仔猪中观察到了针对PEDV的体液免疫应答。值得注意的是,与接种游离COE-S1D-pII蛋白的母猪所产仔猪相比,接种COE-S1D:ND复合物的母猪所产仔猪中检测到更高的PEDV特异性IgG抗体。此外,COE-S1D:ND组仔猪的COE-S1D特异性IgA抗体终点效价高出两倍,PEDV中和抗体水平高出1.6倍。仔猪血清中IgA的存在进一步表明这些抗体的有效转移,有助于系统性免疫和黏膜免疫(60)。总体而言,这些结果表明COE-S1D:ND制剂可能增强体液和黏膜免疫应答,这对保护新生仔猪抵抗PEDV感染至关重要。

有趣的是,5日龄仔猪中测得的针对PEDV的体液免疫应答高于母猪。在分娩前,母猪将大量IgA和IgA从血液主动转运至乳腺,导致初乳抗体浓度比母血清高出数倍。这种选择性转移在分娩后暂时降低了母猪血液中的抗体水平。因此,仔猪血清中IgG、IgA和病毒中和抗体的浓度可在特定时间点暂时超过母猪血清和乳汁中的水平,尤其是在产后前几天。5日龄仔猪保留了早期从初乳中吸收的高水平抗体,因此其血清IgG、IgA和中和抗体水平可能仍高于同时采集的母猪血清和乳汁样本中的水平。我们的观察与先前研究一致,即仔猪中IgG和IgA浓度通常与母猪血清和初乳中的趋势相似(53)。尽管5日龄仔猪血清抗体水平可能暂时超过分娩后立即测得的母猪水平,但仔猪的整体体液免疫应答仍反映了其母体的抗体状态。

多项研究表明,高水平的中和抗体在防御PEDV感染中发挥关键作用(21, 61)。在本研究中,我们旨在开发一种能够诱导更强免疫应答的改良制剂,特别是针对越南流行的主要毒株PEDV G2b的中和活性。在比较针对PEDV的中和抗体效价时,接种游离COE-S1D蛋白的母猪所产仔猪的效价比先前研究中接种COE-pII蛋白的母猪所产仔猪的效价高出约3.8倍(20),在该研究中COE-pII蛋白在仔猪中诱导了针对PEDV G2a的保护性免疫。此外,在比较COE-pII蛋白和COE-S1D-pII蛋白在仔猪中的免疫原性时,我们观察到接种COE-S1D-pII蛋白的仔猪产生的COE特异性IgG、IgA和针对PEDV G2a的中和抗体应答强于接种COE-pII蛋白的仔猪(数据未显示)。这些结果表明COE-S1D-pII可能代表更强的保护相关性,凸显了其在开发针对越南PED的更有效疫苗方面的前景。在另一项实验中,接种50 μg COE-S1D-pII蛋白的仔猪在两次免疫后产生的COE-S1D特异性IgG和IgA以及针对PEDV的中和抗体与商业PEDV疫苗诱导的水平相当(补充图1)。此外,接种COE-S1D:ND混合物的母猪所产仔猪的效价比接种COE-pII蛋白的母猪所产仔猪的效价高出约6.2倍。因此,加入ND纳米粒子显著增强了植物源COE-S1D蛋白的免疫原性。新制剂显著增强了系统性和黏膜免疫,并显著提高了仔猪的中和抗体效价。当前制剂可能对流行的PEDV G2b毒株提供更有效的保护。

各种研究表明,吸附到ND纳米粒子上的抗原可显著增强体液免疫应答和免疫学益处(28, 51, 63, 64)。通过将病毒蛋白(如HA/H7N9)偶联到氧化NDs上形成纳米复合物,粒径范围约为50 nm至500 nm。这些复合物显著增强了疫苗免疫原性:与游离H7蛋白相比,血凝效价提高了高达512倍,而小鼠第二次免疫后H7特异性IgG水平升高超过15.4倍(28)。同样,与HA/H5N1抗原偶联的负氧化NDs导致小鼠中更高的血凝效价以及升高的HA特异性IgG和中和抗体(51)。除病毒蛋白外,NDs还与其他生物活性分子结合以进一步增强免疫应答。例如,羧基化NDs与包封无花果多糖(FP)的NH2-PLGA纳米粒子共价连接,形成NDs-PLGA-FP/OVA复合物。这些复合物促进了抗原摄取,增加了淋巴细胞增殖,上调了MHC II、CD80和CD86的表达,并改变了Th1/Th2细胞平衡。它们还激活了IL-17信号通路,导致细胞因子分泌增加,进而提高OVA特异性IgG水平(65)。重要的是,NDs和荧光NDs(FNDs)与不完全弗氏佐剂(IFA)联合使用时,作为非过敏原性佐剂已证明安全性和有效性。在接种卵清蛋白(OVA)的小鼠模型中,这些基于ND的制剂显著增强了抗体产生并抑制肿瘤生长,对淋巴瘤细胞的抑制作用维持超过35天(52)。

纳米金刚石(NDs)影响抗原呈递和刺激免疫细胞的确切机制仍不清楚。虽然我们的研究主要评估了免疫原性,但先前的研究为NDs的免疫刺激潜力提供了间接证据。NDs和纳米铂已被证明可在体外激活树突状细胞,促进CD4+ T细胞增殖和CD25上调,表明适应性免疫激活(66)。NDs还被证明可触发树突状细胞和巨噬细胞上的受体,诱导强烈的抗病毒样反应,同时保持细胞活力(67)。这些观察结果提示了NDs增强抗原呈递和免疫激活的途径,但仍需进一步的机制性研究。综上所述,这些研究凸显了NDs作为多功能且生物相容性平台的潜力,可用于提高疫苗效力。

尽管我们的数据表明COE-S1D:ND制剂改善了免疫原性,但仍有一些局限性值得注意。重要的是,PEDV在1周龄以下仔猪中引起最高死亡率(3)。虽然我们的主要关注点是接种COE-S1D-pII蛋白或COE-S1D:ND复合物的母猪所产仔猪的免疫应答,但母猪数量有限限制了分析的统计效力。在我们的研究中,每头母猪产下5只仔猪,这些仔猪的免疫应答数据为有意义的分析提供了足够的统计效力。此外,类似研究报道了在免疫试验中使用有限数量母猪的做法(2, 36),支持了我们实验设计的可行性。造成这一限制的主要原因是维持和免疫妊娠母猪的高成本和后勤挑战,以及使用大型动物的伦理考量。此外,在研究期间,非洲猪瘟在越南许多地区广泛爆发,使得招募健康且PEDV阴性的猪群尤为困难。此外,由于长期监测的高成本,我们无法在本研究中延长随访期,而这对确定疫苗提供的保护持续时间很重要。在此,我们未评估细胞免疫应答,如T细胞活化。然而,我们先前的研究表明,另一种植物源COE-pII蛋白可在母猪及其仔猪中诱导IFN-γ应答(20)。此外,未进行攻毒实验以直接评估保护效力,包括暴露于高致病性PEDV毒株后的存活或死亡率。尽管如此,接种COE-S1D-pII蛋白和COE-S1D:ND复合物的母猪所产仔猪中观察到的中和抗体效价高于先前显示可为仔猪提供保护的效价,表明该疫苗具有良好的潜力。未来研究应纳入更大的母猪队列,并结合长期免疫、细胞免疫应答和攻毒实验的评估,以全面评估该纳米疫苗候选物的保护潜力。此外,为实现COE-S1D-pII蛋白的大规模生产,有必要使用适合规模化生产的方法进一步优化纯化工艺。这些努力旨在建立一种能够对越南流行的PEDV毒株诱导更广泛和更持久免疫的纳米疫苗候选物。

## 图5

免疫母猪产后第5天所产仔猪中母源抗体的评估。数据以平均值±标准差(SD)表示。统计学显著差异定义为p < 0.05。(A)使用商品化ELISA试剂盒定量接种COE-S1D-pII或COE-S1D:ND或PBS的母猪(每组n=5)所产仔猪血清中PEDV特异性IgG水平。S/P比值大于0.35的样本被归类为PEDV特异性IgG阳性。(B)通过ELISA测定仔猪血清(每组n=5)中COE-S1D特异性IgA浓度,使用SEC纯化的COE-S1D-pII蛋白作为包被抗原。(C)通过针对高致病性PEDV G2b毒株(100 TCID50/0.1 ml)的病毒中和试验测定仔猪血清中的病毒中和抗体效价。VN效价≥8被认为表明存在PEDV中和抗体。统计学显著性水平表示如下:*p < 0.05;***p < 0.001;****p < 0.0001。

## 数据可用性声明

本研究提出的原始贡献已包含在文章中。